×
About 105,258 results

ALLMedicine™ Squamous Cell Carcinoma Center

Research & Reviews  51,569 results

A novel TGF-β receptor II mutation (I227T/N236D) promotes aggressive phenotype of oral ...
https://doi.org/10.1186/s12885-020-07669-5
BMC Cancer; Son HK, Kim D et. al.

Nov 28th, 2020 - Transforming growth factor-β (TGF-β) signaling is a double-edged sword in cancer development and progression. TGF-β signaling plays a tumor suppressive role during the early stages of tumor development but promotes tumor progression in later stage...

Characterization of wound microbes in epidermolysis bullosa: Results from the epidermol...
https://doi.org/10.1111/pde.14444
Pediatric Dermatology REFERENCES; Levin LE, Shayegan LH et. al.

Nov 28th, 2020 - Patients with epidermolysis bullosa (EB) require care of wounds that are colonized or infected with bacteria. A subset of EB patients are at risk for squamous cell carcinoma, and bacterial-host interactions have been considered in this risk. The E...

Solid organ transplantation worsens the prognosis of patients with cutaneous squamous c...
https://doi.org/10.1002/hed.26546
Head & Neck REFERENCES; Ritter A, Badir S et. al.

Nov 28th, 2020 - Cutaneous squamous cell carcinoma of the head and neck (CSCC-HN) appears to behave more aggressively in immunosuppressed patients. We aimed to investigate this hypothesis by comparing solid organ transplant recipients (SOTR) with CSCC-HN to immuno...

First experiences with Lu-177 PSMA therapy in combination with Pembrolizumab or after p...
https://doi.org/10.2967/jnumed.120.249029
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine; Prasad V, Zengerling F et. al.

Nov 28th, 2020 - Synergistic effects of immunotherapy with pembrolizumab or drugs targeting DNA damage e.g. olaparib could be used to overcome the limitations of radioligand therapy (RLT) with Lu-177 prostate specific membrane antigen (PSMA) in metastasized castra...

The novel target of esophageal squamous cell carcinoma: lncRNA GASL1 regulates cell mig...
https://doi.org/10.1016/j.prp.2020.153289
Pathology, Research and Practice; Ren Y, Guo T et. al.

Nov 28th, 2020 - Long non-coding RNA (lncRNA) Growth-Arrest Associated LncRNA 1 (GASL1) is a lncRNA with a suppressive role in glioma, prostate carcinoma and gastric carcinoma, whereas its involvement in esophageal cancer is unknown. In the present study, we used ...

see more →

Guidelines  131 results

Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ES...
https://doi.org/10.1016/j.annonc.2020.07.011
Annals of Oncology : Official Journal of the European Society for Medical Oncology; Machiels JP, René Leemans C et. al.

Nov 26th, 2020 - Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up.|2020|Machiels JP,René Leemans C,Golusinski W,Grau C,Licitra L,|

Immunotherapy and Beyond: Treatment Options and Potential Markers in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200227/full/

Jul 2nd, 2020 - Head and neck cancers account for approximately 4% of all cancers in the United States1 and are the eighth most common cancer affecting men in the United States.2 The diagnosis of recurrent or metastatic head and neck squamous cell carcinoma (R/M ...

FDA approves nivolumab for esophageal squamous cell carcinoma
https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-nivolumab-esophageal-squamous-cell-carcinoma
FDA

Jun 9th, 2020 - On June 10, 2020, the Food and Drug Administration approved nivolumab (OPDIVO, Bristol-Myers Squibb Co.) for patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and p...

Key Efficacy End Points Upheld at 3 Years for Cemiplimab in CSCC
https://www.targetedonc.com/view/key-efficacy-end-points-upheld-at-3-years-for-cemiplimab-in-cscc

May 30th, 2020 - Three-year follow-up data from the phase 2 EMPOWER-CSCC-1 trial (NCT02760498) demonstrated a clinically meaningful survival and duration of response (DOR) improvement with cemiplimab-rwlc (Libtayo) in patients with advanced cutaneous squamous cell...

Longer Follow-Up for Cemiplimab Confirms Superior Efficacy Over Other Regimens for CSCC
https://www.onclive.com/conference-coverage/asco-2020/longer-followup-for-cemiplimab-confirms-superior-efficacy-over-other-regimens-for-cscc

May 30th, 2020 - In the phase 2 trial EMPOWER-CSCC-1 (NCT02760498), up to 3 years of follow-up showed continued response rates, and a clinically meaningful survival and duration of response (DOR) for cemiplimab-rwlc (Libtayo) in patients with advanced cutaneous sq...

see more →

Drugs  31 results see all →

Clinicaltrials.gov  52,551 results

Bleomycin - bleomycin injection, powder, lyophilized, for solution-Amneal Pharmaceuticals LLC
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=38955939-8d1e-4db2-9aed-3bab72ca5f8f

Dec 26th, 2020 - Palliation and treatment adjutant to surgery and radiation therapy of the following neoplasms: Squamous cell carcinoma of the skin, head and neck, and esophagus (primary indication). Squamous cell carcinoma of the larynx, penis and uterine cervix....

A novel TGF-β receptor II mutation (I227T/N236D) promotes aggressive phenotype of oral ...
https://doi.org/10.1186/s12885-020-07669-5
BMC Cancer; Son HK, Kim D et. al.

Nov 28th, 2020 - Transforming growth factor-β (TGF-β) signaling is a double-edged sword in cancer development and progression. TGF-β signaling plays a tumor suppressive role during the early stages of tumor development but promotes tumor progression in later stage...

Characterization of wound microbes in epidermolysis bullosa: Results from the epidermol...
https://doi.org/10.1111/pde.14444
Pediatric Dermatology REFERENCES; Levin LE, Shayegan LH et. al.

Nov 28th, 2020 - Patients with epidermolysis bullosa (EB) require care of wounds that are colonized or infected with bacteria. A subset of EB patients are at risk for squamous cell carcinoma, and bacterial-host interactions have been considered in this risk. The E...

Solid organ transplantation worsens the prognosis of patients with cutaneous squamous c...
https://doi.org/10.1002/hed.26546
Head & Neck REFERENCES; Ritter A, Badir S et. al.

Nov 28th, 2020 - Cutaneous squamous cell carcinoma of the head and neck (CSCC-HN) appears to behave more aggressively in immunosuppressed patients. We aimed to investigate this hypothesis by comparing solid organ transplant recipients (SOTR) with CSCC-HN to immuno...

First experiences with Lu-177 PSMA therapy in combination with Pembrolizumab or after p...
https://doi.org/10.2967/jnumed.120.249029
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine; Prasad V, Zengerling F et. al.

Nov 28th, 2020 - Synergistic effects of immunotherapy with pembrolizumab or drugs targeting DNA damage e.g. olaparib could be used to overcome the limitations of radioligand therapy (RLT) with Lu-177 prostate specific membrane antigen (PSMA) in metastasized castra...

see more →

News  933 results

SLN Biopsy for Oral Cancer? French Surgeons Say 'Oui'
https://www.medscape.com/viewarticle/940134

Nov 1st, 2020 - French investigators are suggesting that sentinel lymph node (SLN) biopsy should replace neck lymph node dissection as the new standard for detecting occult metastases in patients with T1-T2N0 oral and oropharyngeal squamous cell carcinoma. In a r...

Icotinib Plus Radiotherapy Ups Survival in Elderly With Esophageal Cancer
https://www.staging.medscape.com/viewarticle/939190

Oct 18th, 2020 - NEW YORK (Reuters Health) - Icotinib with concurrent radiotherapy (RT) boosts survival and may have other benefits compared to RT alone in elderly patients with unresectable esophageal squamous cell carcinoma, according to Chinese researchers. Dr....

Icotinib Plus Radiotherapy Ups Survival in Elderly With Esophageal Cancer
https://www.medscape.com/viewarticle/939190

Oct 18th, 2020 - NEW YORK (Reuters Health) - Icotinib with concurrent radiotherapy (RT) boosts survival and may have other benefits compared to RT alone in elderly patients with unresectable esophageal squamous cell carcinoma, according to Chinese researchers. Dr....

Antibiotic-Resistant Cough and Back Pain in a 63-Year-Old
https://reference.medscape.com/viewarticle/842258_4

Oct 15th, 2020 - Non-small cell lung cancer accounts for approximately 85% of all lung cancers. Histologically, it is divided into adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Patients with non-small cell lung cancer require a complete stagin...

'Contrary' to Wide Belief, Abscopal Effect Is Rare in Cancer
https://www.medscape.com/viewarticle/938714

Oct 6th, 2020 - There was no evidence of an 'abscopal effect' with the addition of limited radiation therapy to nivolumab (Opdivo) in patients with metastatic head and neck squamous cell carcinoma, according to new results from a randomized trial.  The phase 2, s...

see more →

Patient Education  43 results see all →